Core Viewpoint - HUTCHMED is set to announce its final results for the year ended December 31, 2024, on March 19, 2025, with an invitation for analysts and investors to join a conference call and audio webcast presentation [1][2]. Company Overview - HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [3]. - The company has successfully brought drug candidates from in-house discovery to market, with its first three medicines marketed in China, and the first also approved in the US, Europe, and Japan [3]. Event Details - The English conference call and audio webcast will occur at 8:00 am EDT / 12:00 pm GMT / 8:00 pm HKT on March 19, 2025, with a Chinese (Putonghua) webcast following on March 20, 2025 [2]. - Both webcasts will be available live on the company website, and a replay will be accessible shortly after the event [2].
HUTCHMED to Announce 2024 Final Results